Visão geral da empresa
A biotechnology enterprise focused on innovating, developing, and commercializing next-generation immunotherapies, ImmunityBio, Inc. operates by creating biological platforms designed to activate a patient's immune system to deliver durable protection against cancer and infectious diseases. The company functions within the healthcare sector, specifically the biotechnology industry, an environment characterized by high research and development expenditures and reliance on proprietary intellectual property to drive future commercialization. ImmunityBio, Inc. currently holds a market capitalization of $7.21B, generates $113.29M in annual revenue, and employs 684 individuals across its operational footprint. The combination of a $7.21B market cap and $113.29M in revenue indicates that the market assigns a significant premium to the company's pipeline potential, suggesting that investors value the long-term commercial prospects of its immunotherapy platforms far above its current revenue generation capabilities.
Saúde financeira
ImmunityBio, Inc. reported a revenue of $113.29M over the trailing twelve months, yet recorded a net income of $-351,398,016, revealing a substantial divergence where operating expenses and R&D costs significantly outweigh current sales, which is typical for a growth-stage biotechnology firm. The company's EBITDA stands at $-240,602,000, indicating that earnings before interest, taxes, depreciation, and amortization are deeply negative due to heavy investment in clinical trials and platform development. Free cash flow is reported at $-213,356,992, which signifies that the company is burning cash at a rapid pace and relies entirely on external capital markets to fund its operations rather than internal cash generation. The gross margin is 99.3%, reflecting the low cost of goods sold relative to revenue in biotechnology, whereas the operating margin of -169.0% and profit margin of 0.0% highlight the intense pressure from overhead and development costs that erade profitability before the break-even point is reached. Total cash reserves of $242.82M are substantially lower than total debt of $844.72M, while the debt-to-equity ratio is listed as N/A, indicating a highly leveraged balance sheet structure relative to its equity base. The current ratio of 5.10 suggests a strong short-term liquidity position, implying that the company possesses ample current assets to cover its short-term liabilities despite its negative earnings. Return on Equity is N/A due to the negative equity position, while Return on Assets is -36.2%, which reveals that management is currently utilizing the asset base to generate losses rather than returns, a common characteristic of capital-intensive biotechnology companies in pre-profitability phases.
Avaliação de valorização
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -349.00, implying that the market is pricing the stock based on future expectations rather than current profitability metrics. The price-to-book ratio is -14.10, a negative figure that indicates the market value of the company is significantly below its book value, reflecting investor caution regarding the recoverability of assets or the high cost of the intangible biological platforms. The price-to-sales ratio stands at 63.63, and the EV/EBITDA is -32.33, metrics that suggest the market is willing to pay a massive multiple of sales for the company, valuing the potential of its immunotherapy pipeline above the risks associated with its current financial losses. The 52-week high is $12.43 and the 52-week low is $1.83, meaning the current price sits somewhere within this wide range, subject to market sentiment regarding clinical trial outcomes and regulatory approvals. The beta value is 0.06, which indicates that the stock exhibits extremely low volatility relative to the broader market, moving independently of general market swings and behaving more like a defensive asset or a speculative deep-value play rather than a traditional high-volatility biotech stock.
Growth & Income
Revenue growth year-over-year is 407.0%, demonstrating an aggressive expansion in sales, whereas earnings growth is N/A, indicating that profitability has not yet been achieved to support a growth rate comparison. The absence of a positive earnings growth rate implies that the company is still in a capital-intensive phase where revenue expansion is prioritized over immediate profit generation. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status is consistent with the company's strategy of reinvesting all available earnings and cash flow back into research, development, and clinical trials to fuel pipeline growth rather than returning capital to investors. The overall growth and income profile is characterized by explosive revenue expansion and zero dividend income, positioning the stock as a pure-play growth vehicle for investors seeking exposure to next-generation immunotherapies without current cash return.